Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Aparicio, Luis A ^a   Castosa, Raquel ^a   Haz Conde, Mar ^a   Rodríguez, Marta ^a   Blanco, Moisés ^a   Valladares, Manuel ^a   Figueroa, Angélica ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Bladder cancer; Cell cell contacts; E cadherin; Microtubule; Vinflunine

Indexed keywords

CELL PROTEIN; HAKAI PROTEIN; NERVE CELL ADHESION MOLECULE; PROTEASOME; UNCLASSIFIED DRUG; VIMENTIN; VINFLUNINE; VINBLASTINE;

APOPTOSIS; ARTICLE; BLADDER EPITHELIUM; BLADDER TUMOR; CANCER INHIBITION; CELL ADHESION; CELL DIFFERENTIATION; CELL VIABILITY ASSAY; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MICROTUBULE; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL CULTURE; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROTUBULES; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84903862328     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-507     Document Type: Article

References (70)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
2. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med 1990, 322(16):1129-1138.
3. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009, 55(4):815-825.
4. Nollet F, Kools P, van Roy F. Phylogenetic analysis of the cadherin superfamily allows identification of six major subfamilies besides several solitary members. J Mol Biol 2000, 299(3):551-572.
5. Perez-Moreno M, Jamora C, Fuchs E. Sticky business: orchestrating cellular signals at adherens junctions. Cell 2003, 112(4):535-548.
6. Yonemura S. Cadherin-actin interactions at adherens junctions. Curr Opin Cell Biol 2011, 23(5):515-522.
7. Christofori G. New signals from the invasive front. Nature 2006, 441(7092):444-450.
8. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008, 14(6):818-829.
9. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139(5):871-890.
10. Yun SJ, Kim WJ. Role of the Epithelial-Mesenchymal Transition in Bladder Cancer: From Prognosis to Therapeutic Target. Korean J Urol 2013, 54(10):645-650.
11. Chen J, Han Q, Pei D. EMT and MET as paradigms for cell fate switching. J Mol Cell Biol 2012, 4(2):66-69.
12. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994, 1198(1):11-26.
13. Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM, Birchmeier W. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 1993, 120(3):757-766.
14. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998, 392(6672):190-193.
15. Shimazui T, Schalken JA, Giroldi LA, Jansen CF, Akaza H, Koiso K, Debruyne FM, Bringuier PP. Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res 1996, 56(18):4154-4158.
16. De Wever O, Pauwels P, De Craene B, Sabbah M, Emami S, Redeuilh G, Gespach C, Bracke M, Berx G. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol 2008, 130(3):481-494.
17. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009, 28(1-2):15-33.
18. Mendez MG, Kojima S, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J 2010, 24(6):1838-1851.
19. Aparicio LA, Valladares M, Blanco M, Alonso G, Figueroa A. Biological influence of Hakai in cancer: a 10-year review. Cancer Metastasis Rev 2012, 31(1-2):375-386.
20. Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J, García De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000, 2(2):84-89.
21. Fujita Y, Krause G, Scheffner M, Zechner D, Leddy H, Behrens J, Sommer T, Birchmeier W. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol 2002, 4(3):222-231.
22. Swaminathan G, Cartwright CA. Rack1 promotes epithelial cell-cell adhesion by regulating E-cadherin endocytosis. Oncogene 2011, 31(3):376-389.
23. Janda E, Nevolo M, Lehmann K, Downward J, Beug H, Grieco M. Raf plus TGFbeta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin. Oncogene 2006, 25(54):7117-7130.
24. Zhou WJ, Geng ZH, Chi S, Zhang W, Niu XF, Lan SJ, Ma L, Yang X, Wang LJ, Ding YQ, Geng JG. Slit-Robo signaling induces malignant transformation through Hakai-mediated E-cadherin degradation during colorectal epithelial cell carcinogenesis. Cell Res 2011, 21(4):609-626.
25. Figueroa A, Kotani H, Toda Y, Mazan-Mamczarz K, Mueller E, Otto A, Disch L, Norman M, Ramdasi R, Keshtgar M, Gorospe M, Fujita Y. Novel roles of hakai in cell proliferation and oncogenesis. Mol Biol Cell 2009, 20(15):3533-3542.
26. Figueroa A, Fujita Y, Gorospe M. Hacking RNA: Hakai promotes tumorigenesis by enhancing the RNA-binding function of PSF. Cell Cycle 2009, 8(22):3648-3651.
27. Rodríguez-Rigueiro T, Valladares-Ayerbes M, Haz-Conde M, Aparicio LA, Figueroa A. Hakai reduces cell-substratum adhesion and increases epithelial cell invasion. BMC Cancer 2011, 11:474.
28. Abella V, Valladares M, Rodriguez T, Haz M, Blanco M, Tarrío N, Iglesias P, Aparicio LA, Figueroa A. miR-203 Regulates Cell Proliferation through Its Influence on Hakai Expression. PLoS One 2012, 7(12):e52568.
29. Jordan MA, Horwitz SB, Lobert S, Correia JJ. Exploring the mechanisms of action of the novel microtubule inhibitor vinflunine. Semin Oncol 2008, 35(3 Suppl 3):S6-S12.
30. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004, 4(4):253-265.
31. Gerullis H, Ecke T, Eimer C, Wishahi M, Otto T. Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma: a review. Anticancer Drugs 2011, 22(1):9-17.
32. Gerullis H. Vinflunine: a fluorinated vinca alkaloid for bladder cancer therapy. Drugs Today (Barc) 2011, 47(1):17-25.
33. Aparicio LM, Pulido EG, Gallego GA. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity. Anticancer Drugs 2012, 23(1):1-11.
34. Pasquier E, Honoré S, Braguer D. Microtubule-targeting agents in angiogenesis: where do we stand?. Drug Resist Updat 2006, 9(1-2):74-86.
35. Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009, 15(8):2594-2601.
36. Honoré S, Pagano A, Gauthier G, Bourgarel-Rey V, Verdier-Pinard P, Civiletti K, Kruczynski A, Braguer D. Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites. Mol Cancer Ther 2008, 7(7):2080-2089.
37. Akhmanova A, Yap AS. Organizing junctions at the cell-cell interface. Cell 2008, 135(5):791-793.
38. Akhmanova A, Stehbens SJ, Yap AS. Touch, grasp, deliver and control: functional cross-talk between microtubules and cell adhesions. Traffic 2009, 10(3):268-274.
39. Stehbens SJ, Paterson AD, Crampton MS, Shewan AM, Ferguson C, Akhmanova A, Parton RG, Yap AS. Dynamic microtubules regulate the local concentration of E-cadherin at cell-cell contacts. J Cell Sci 2006, 119(Pt 9):1801-1811.
40. Stehbens SJ, Akhmanova A, Yap AS. Microtubules and cadherins: a neglected partnership. Front Biosci (Landmark Ed) 2009, 14:3159-3167.
41. Han SP, Yap AS. The cytoskeleton and classical cadherin adhesions. Subcell Biochem 2012, 60:111-135.
42. Shtutman M, Chausovsky A, Prager-Khoutorsky M, Schiefermeier N, Boguslavsky S, Kam Z, Fuchs E, Geiger B, Borisy GG, Bershadsky AD. Signaling function of alpha-catenin in microtubule regulation. Cell Cycle 2008, 7(15):2377-2383.
43. Rodríguez Rigueiro T, Valladares Ayerbes M, Haz Conde M, Blanco M, Aparicio G, Fernández Puente P, Blanco FJ, Lorenzo MJ, Aparicio LA, Figueroa A. A novel procedure for protein extraction from formalin-fixed paraffin-embedded tissues. Proteomics 2011, 11(12):2555-2559.
44. Bonfil RD, Russo DM, Binda MM, Delgado FM, Vincenti M. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol 2002, 7(4):159-166.
45. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 1994, 78(5):761-771.
46. Zhang Z, Zhou Y, Qian H, Shao G, Lu X, Chen Q, Sun X, Chen D, Yin R, Zhu H, Shao Q, Xu W. Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells. Cell Death Dis 2013, 4:e633.
47. Guichet PO, Bieche I, Teigell M, Serguera C, Rothhut B, Rigau V, Scamps F, Ripoll C, Vacher S, Taviaux S, Chevassus H, Duffau H, Mallet J, Susini A, Joubert D, Bauchet L, Hugnot JP. Cell death and neuronal differentiation of glioblastoma stem-like cells induced by neurogenic transcription factors. Glia 2013, 61(2):225-239.
48. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE, Ahmadi R, Lohr J, Dictus C, Gdynia G, Combs SE, Goidts V, Helmke BM, Eckstein V, Roth W, Beckhove P, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende C. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 2010, 16(10):2715-2728.
49. Seigel GM. Differentiation potential of human retinoblastoma cells. Curr Pharm Biotechnol 2011, 12(2):213-216.
50. Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2003, 2(5):427-436.
51. Bryan RT, Tselepis C. Cadherin switching and bladder cancer. J Urol 2010, 184(2):423-431.
52. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005, 5(9):675-688.
53. Deep G, Gangar S, Agarwal C, Agarwal R. Role of E-cadherin in anti-migratory and anti-invasive efficacy of silibinin in prostate cancer cells. Cancer Prev Res (Phila) 2011, 4(8):1222-1232.
54. Wu K, Zeng J, Li L, Fan J, Zhang D, Xue Y, Zhu G, Yang L, Wang X, He D. Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors. Oncol Rep 2010, 23(6):1545-1552.
55. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008, 14(5):1478-1486.
56. Laplante I, Béliveau R, Paquin J. RhoA/ROCK and Cdc42 regulate cell-cell contact and N-cadherin protein level during neurodetermination of P19 embryonal stem cells. J Neurobiol 2004, 60(3):289-307.
57. Lehmann M, Fournier A, Selles-Navarro I, Dergham P, Sebok A, Leclerc N, Tigyi G, McKerracher L. Inactivation of Rho signaling pathway promotes CNS axon regeneration. J Neurosci 1999, 19(17):7537-7547.
58. Luo L. Rho GTPases in neuronal morphogenesis. Nat Rev Neurosci 2000, 1(3):173-180.
59. Yuan XB, Jin M, Xu X, Song YQ, Wu CP, Poo MM, Duan S. Signalling and crosstalk of Rho GTPases in mediating axon guidance. Nat Cell Biol 2003, 5(1):38-45.
60. Gao X, Bian W, Yang J, Tang K, Kitani H, Atsumi T, Jing N. A role of N-cadherin in neuronal differentiation of embryonic carcinoma P19 cells. Biochem Biophys Res Commun 2001, 284(5):1098-1103.
61. Kitase Y, Shuler CF. Microtubule disassembly prevents palatal fusion and alters regulation of the E-cadherin/catenin complex. Int J Dev Biol 2013, 57(1):55-60.
62. Kitase Y, Shuler CF. Multi-layered hypertrophied MEE formation by microtubule disruption via GEF-H1/RhoA/ROCK signaling pathway. Dev Dyn 2012, 241(7):1169-1182.
63. Brieher WM, Yap AS. Cadherin junctions and their cytoskeleton(s). Curr Opin Cell Biol 2013, 25(1):39-46.
64. Meng W, Mushika Y, Ichii T, Takeichi M. Anchorage of microtubule minus ends to adherens junctions regulates epithelial cell-cell contacts. Cell 2008, 135(5):948-959.
65. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-Schughart LA, Knuechel R, Kirchner T. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 2001, 98(18):10356-10361.
66. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006, 66(23):11271-11278.
67. Ocaña OH, Córcoles R, Fabra A, Moreno-Bueno G, Acloque H, Vega S, Barrallo-Gimeno A, Cano A, Nieto MA. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012, 22(6):709-724.
68. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012, 22(6):725-736.
69. Brabletz T. EMT and MET in metastasis: where are the cancer stem cells?. Cancer Cell 2012, 22(6):699-701.
70. Nieto MA, Cano A. The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol 2012, 22(5-6):361-368.